Ftse Mib
33.746,66
-1,60%
DAX
17.932,17
-1,10%
S&P 500
5.015,22
-0,41%
NASDAQ Composite
15.598,08
-0,38%
Bitcoin
56.802,68
-6,28%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Harrow Inc (HROW) Harrow Inc (HROW) Notizie

Harrow Inc

HROW
10,39
0,20 (1,96%)
Ultimo aggiornamento: 19:00:14
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
25/4/202413:00BWHarrow Will Release First Quarter 2024 Financial Results..
02/4/202414:16BWMelt Pharmaceuticals Closes $24 Million Series B Preferred..
20/3/202412:15IHMARKETNEWSJPMorgan boosts dividends, Chipotle unveils 50:1 stock..
19/3/202422:45BWHarrow Announces Fourth Quarter and Year-End 2023 Financial..
19/3/202412:27IHMARKETNEWSUS Index Futures Decline Ahead of Federal Reserve Meeting,..
06/3/202412:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202413:00BWHarrow Will Release Fourth Quarter and Year-End 2023..
22/2/202401:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202401:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202422:15EDGAR2Form 8-K - Current report
15/2/202422:01BWHarrow Licenses Canadian Rights to Apotex for Five Branded..
09/2/202422:05EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/2/202413:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/1/202422:30EDGAR2Form 8-K - Current report
29/1/202421:26EDGAR2Form SC 13G - Statement of acquisition of beneficial..
29/1/202413:00BWHarrow Announces New Appointments to its Board of Directors
11/1/202413:00BWHarrow Announces Availability of VEVYE® (Cyclosporine..
09/1/202416:16EDGAR2Form SC 13G - Statement of acquisition of beneficial..
03/1/202414:00EDGAR2Form 8-K - Current report
03/1/202413:15BWMelt Pharmaceuticals Provides Corporate Update
03/1/202413:00BWHarrow Partners with Leading Healthcare Market Access..
29/11/202313:00BWHarrow Completes Transfer of the TRIESENCE® New Drug..
20/11/202313:00BWHarrow to Present at Two Investor Conferences in November
16/11/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/11/202301:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202322:38EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202322:34EDGAR2Form 8-K - Current report
13/11/202322:01BWHarrow Announces Third Quarter 2023 Financial Results
03/11/202321:52EDGAR2Form 8-K - Current report
30/10/202313:00BWHarrow Will Release Third Quarter 2023 Financial Results on..
24/10/202313:00BWHarrow Completes Transfer of NDAs and Launches FLAREX®,..
29/9/202322:01EDGAR2Form 8-K - Current report
29/9/202314:00BWHarrow Health, Inc. Changes Corporate Name to Harrow, Inc.
26/9/202314:00BWMelt Pharmaceuticals Announces Exclusive Development and..
21/9/202300:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/8/202313:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/8/202322:26EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/8/202322:05EDGAR2Form 8-K - Current report
09/8/202322:01BWHarrow Announces Second Quarter 2023 Financial Results
31/7/202313:00BWHarrow Launches VIGAMOX® in the U.S.
26/7/202315:00BWHarrow to Announce Second Quarter 2023 Financial Results on..
21/7/202322:02EDGAR2Form 8-K - Current report
21/7/202301:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/7/202301:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/7/202323:19EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
19/7/202313:00BWHarrow Prices $60 Million Public Offering of Common Stock
19/7/202304:55BWHarrow erwirbt US-amerikanische und kanadische..
18/7/202323:03EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
18/7/202323:00BWHarrow Acquires Santen’s Branded Ophthalmic Portfolio
18/7/202322:59EDGAR2Form 8-K - Current report
Apertura: 10,24 Min: 10,04 Max: 10,44
Chiusura: 10,19

La tua Cronologia

NASDAQ
HROW
Harrow
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network